No Data
Protara Therapeutics Reports Q1 2025 Financial Results
Scotiabank Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $12
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $23
Protara Therapeutics' TARA-002: A Promising Alternative for NMIBC With Strong Efficacy and Safety Profile
Protara Therapeutics | 10-Q: Quarterly report
Protara Therapeutics | 8-K: Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Adria87 :
Magic 1983 : what the fuck is goin on here
Magic 1983 : com on baby fly